MediciNova (MNOV) Stock Price, News & Analysis

Company Overview

MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness. MediciNova is evaluating ibudilast in multiple late-stage and exploratory studies, including progressive multiple sclerosis, amyotrophic lateral sclerosis (ALS) and substance use disorders such as opioid and alcohol dependence. Ibudilast’s mechanism of action involves modulation of glial cell activity in the central nervous system, aiming to slow neurodegeneration and reduce inflammation.

Another key compound, MN-001 (tipelukast), is a leukotriene receptor antagonist in development for idiopathic pulmonary fibrosis (IPF), nonalcoholic steatohepatitis (NASH) and diabetic nephropathy. MN-001 has completed Phase II trials in IPF patients and is being positioned as a potential treatment for a range of progressive fibrotic conditions. MediciNova also maintains a preclinical respiratory portfolio, including β1-adrenergic agonists aimed at acute lung injury and chronic obstructive pulmonary disease (COPD).

MediciNova leverages partnerships with pharmaceutical companies in Japan and globally to support late-stage trials and potential commercialization. The company’s multidisciplinary leadership team brings together expertise in clinical development, regulatory affairs and global business development to advance its pipeline. Through a combination of in-house research and strategic alliances, MediciNova seeks to deliver new therapies across multiple therapeutic areas with significant market opportunities.

Key Stats

• Today's Range: $1.22 to $1.25
• 50-Day Range: $1.22 to $1.46
• 52-Week Range: $1.13 to $2.55
• Volume: 18,306 shs
• Average Volume: 63,951 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

MediciNova Stock Analysis - MarketRank™

MediciNova scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

MediciNova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

MediciNova has a consensus price target of $7.00, representing about 460.0% upside from its current price of $1.25.

Amount of Analyst Coverage

MediciNova has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for MediciNova are expected to remain at ($0.24) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of MediciNova is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MediciNova is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MediciNova has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.32% of the float of MediciNova has been sold short.

Short Interest Ratio / Days to Cover

MediciNova has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MediciNova has recently increased by 17.82%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MediciNova does not currently pay a dividend.

Dividend Growth

MediciNova does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.32% of the float of MediciNova has been sold short.

Short Interest Ratio / Days to Cover

MediciNova has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MediciNova has recently increased by 17.82%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.98

News Sentiment

MediciNova has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for MediciNova this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MediciNova insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.60% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.90% of the stock of MediciNova is held by institutions.

MNOV Stock Analysis - Frequently Asked Questions

How have MNOV shares performed this year?

MediciNova's stock was trading at $2.10 on January 1st, 2025. Since then, MNOV shares have decreased by 40.5% and is now trading at $1.25.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings data on Thursday, August, 14th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The biopharmaceutical company had revenue of $0.14 million for the quarter.

Who are MediciNova's major shareholders?

Top institutional investors of MediciNova include Bank of America Corp DE, Bridgeway Capital Management LLC and SBI Securities Co. Ltd. (0.09%).
View institutional ownership trends.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MediciNova own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MediciNova investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Inuvo (INUV).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MNOV
• CIK: 1226616
• Web: medicinova.com
• Phone: (858) 373-1500
• Fax: 858-404-0048
• Employees: 10
• Year Founded: 2000

Price Target and Rating

• Average Price Target for MediciNova: $7.00
• High Price Target: $9.00
• Low Price Target: $5.00
• Potential Upside/Downside: +460.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.04 million
• Net Margins: N/A
• Pretax Margin: -8,745.18%
• Return on Equity: -23.12%
• Return on Assets: -21.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.26
• Quick Ratio: 13.26

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.07 per share
• Price / Book: 1.17

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: 0.43